Weijia Wang1, Liang Yan1, Xiaoya Guan1, Bin Dong2, Min Zhao3, Jianhui Wu1, Xiuyun Tian1, Chunyi Hao1. 1. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, China. 2. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, China. 3. Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Abstract
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. The tumor microenvironment (TME) is vital for tumor immune responses, leading to resistance to chemotherapy and poor prognosis of PDAC patients. This study aimed to provide a comprehensive evaluation of the immune genes and microenvironment in PDAC that might help in predicting prognosis and guiding clinical treatments. METHODS: We developed a prognosis-associated immune signature (i.e., PAIS) based on immune-associated genes to predict the overall survival of patients with PDAC. The clinical significance and immune landscapes of the signature were comprehensively analyzed. RESULTS: Owing to gene expression profiles from TCGA database, functional enrichment analysis revealed a significant difference in the immune response between PDAC and normal pancreas. Using transcriptome data analysis of a training set, we identified an immune signature represented by 5 genes (ESR2, IDO1, IL20RB, PPP3CA, and PLAU) related to the overall survival of patients with PDAC, significantly. This training set was well-validated in a test set. Our results indicated a clear association between a high-risk score and a very poor prognosis. Stratification analysis and multivariate Cox regression analysis revealed that PAIS was an important prognostic factor. We also found that the risk score was positively correlated with the inflammatory response, antigen-presenting process, and expression level of some immunosuppressive checkpoint molecules (e.g., CD73, PD-L1, CD80, and B7-H3). These results suggested that high-risk patients had a suppressed immune response. However, they could respond better to chemotherapy. In addition, PAIS was positively correlated with the infiltration of M2 macrophages in PDAC. CONCLUSIONS: This study highlighted the relationship between the immune response and prognosis in PDAC and developed a clinically feasible signature that might serve as a powerful prognostic tool and help further optimize the cancer therapy paradigm.
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is one of the highest fatality rate cancers with poor survival rates. The tumor microenvironment (TME) is vital for tumor immune responses, leading to resistance to chemotherapy and poor prognosis of PDAC patients. This study aimed to provide a comprehensive evaluation of the immune genes and microenvironment in PDAC that might help in predicting prognosis and guiding clinical treatments. METHODS: We developed a prognosis-associated immune signature (i.e., PAIS) based on immune-associated genes to predict the overall survival of patients with PDAC. The clinical significance and immune landscapes of the signature were comprehensively analyzed. RESULTS: Owing to gene expression profiles from TCGA database, functional enrichment analysis revealed a significant difference in the immune response between PDAC and normal pancreas. Using transcriptome data analysis of a training set, we identified an immune signature represented by 5 genes (ESR2, IDO1, IL20RB, PPP3CA, and PLAU) related to the overall survival of patients with PDAC, significantly. This training set was well-validated in a test set. Our results indicated a clear association between a high-risk score and a very poor prognosis. Stratification analysis and multivariate Cox regression analysis revealed that PAIS was an important prognostic factor. We also found that the risk score was positively correlated with the inflammatory response, antigen-presenting process, and expression level of some immunosuppressive checkpoint molecules (e.g., CD73, PD-L1, CD80, and B7-H3). These results suggested that high-risk patients had a suppressed immune response. However, they could respond better to chemotherapy. In addition, PAIS was positively correlated with the infiltration of M2 macrophages in PDAC. CONCLUSIONS: This study highlighted the relationship between the immune response and prognosis in PDAC and developed a clinically feasible signature that might serve as a powerful prognostic tool and help further optimize the cancer therapy paradigm.
Authors: Jeffery Ho; Xianchun Li; Lin Zhang; Yonghao Liang; Wei Hu; Johnny C W Yau; Hung Chan; Tony Gin; Matthew T V Chan; Gary Tse; William K K Wu Journal: Semin Cancer Biol Date: 2018-04-26 Impact factor: 15.707
Authors: Alex B Blair; Jennifer Kleponis; Dwayne L Thomas; Stephen T Muth; Adrian G Murphy; Victoria Kim; Lei Zheng Journal: J Clin Invest Date: 2019-03-18 Impact factor: 14.808
Authors: Joanna M Karasinska; James T Topham; Steve E Kalloger; Daniel J Renouf; David F Schaeffer; Gun Ho Jang; Robert E Denroche; Luka Culibrk; Laura M Williamson; Hui-Li Wong; Michael K C Lee; Grainne M O'Kane; Richard A Moore; Andrew J Mungall; Malcolm J Moore; Cassia Warren; Andrew Metcalfe; Faiyaz Notta; Jennifer J Knox; Steven Gallinger; Janessa Laskin; Marco A Marra; Steven J M Jones Journal: Clin Cancer Res Date: 2019-09-03 Impact factor: 12.531
Authors: Le Tao; Jianxin Qiu; Spencer Slavin; Zhenyu Ou; Zhihong Liu; Jifu Ge; Li Zuo; Elizabeth A Guancial; Edward M Messing; Chawnshang Chang; Shuyuan Yeh Journal: Cancer Lett Date: 2018-04-22 Impact factor: 8.679
Authors: Magdalena Polanczyk; Srikanth Yellayi; Alex Zamora; Sandhya Subramanian; Micah Tovey; Arthur A Vandenbark; Halina Offner; James F Zachary; Parley D Fillmore; Elizabeth P Blankenhorn; Jan-Ake Gustafsson; Cory Teuscher Journal: Am J Pathol Date: 2004-06 Impact factor: 4.307